NCT04681079

Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19

A 2-Period, Crossover Study to Assess the Impact of Nebulizer With Filtered Mouthpiece vs MDI With Spacer on Viral Load in Rooms of Subjects With Mild to Moderate COVID-19

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 14 (actual)
• Sponsor: Theravance Biopharma · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A randomized, 2-period crossover, single-center, open-label study for viral sample collection. After initiation of inhaled therapy with nebulizer or MDI, cascade impactors and surface samplers will be used to assess viral loads in rooms of subjects with COVID-19.

Detailed description

Observational Study Model = Other \[non-treatment; impact on external location (rooms and surfaces)\] Time Perspective = Other \[viral load samples taken at various time points after nebulization or MDI administered\] Sampling Method = Non-probability sample \[to be described by study team\]

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	albuterol sulfate (MDI)	albuterol sulfate inhalation aerosol delivered via metered-dose inhaler (MDI) with spacer
DRUG	albuterol sulfate (nebulizer)	albuterol sulfate inhalation aerosol delivered via nebulizer with filtered mouthpiece

Timeline

• Start date: 2021-05-04
• Primary completion: 2021-11-22
• Completion: 2022-01-18
• First posted: 2020-12-23
• Last updated: 2022-01-28

Locations

1 site across 1 country: United States